Answers are grounded in this paper and cite their sources.
Platelet-rich fibrin (PRF), a second-generation autologous platelet concentrate, is used as an adjunct in oral and maxillofacial regeneration. This narrative review integrates mechanistic evidence for osteogenic signaling, angiogenesis, immunomodulation, and redox regulation with clinical evidence across sinus floor elevation, post-extraction socket healing, alveolar ridge preservation, periodontal intrabony defects, peri-implant procedures, alveolar cleft grafting, regenerative endodontics, and medication-related osteonecrosis of the jaw. This investigator-directed narrative review was based primarily on PubMed, with targeted searches and reference-list screening, and no formal risk-of-bias assessment. Mechanistic support is strongest for signaling through bone morphogenetic protein 2 and runt-related transcription factor 2, and for vascular endothelial growth factor-related angiogenesis. Evidence for other osteogenic pathways is less extensive, while osteoimmune and redox evidence remains predominantly preclinical. Clinical translation is indication-specific. Early soft-tissue healing and postoperative pain reduction are the most frequently reported favorable outcomes, mainly from short-term, extraction-based studies of ungraded certainty. Hard-tissue and dimensional outcomes are inconsistent and vary with defect size, comparator, PRF format, and centrifugation protocol. Current evidence supports a context-dependent adjunctive role for PRF. Future trials should standardize protocols and platelet-dose reporting, isolate PRF as the tested variable, and prespecify clinically meaningful hard-tissue and patient-reported outcomes.
No takes yet. Share an insight, caveat, or question.
Stefanescu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: